The XVIII International Parvovirus Workshop Rimini, Italy, 14-17 June 2022

Giorgio Gallinella; Antonio Marchini

doi:10.3390/v15102129

The XVIII International Parvovirus Workshop Rimini, Italy, 14-17 June 2022

Viruses. 2023 Oct 20;15(10):2129. doi: 10.3390/v15102129.

Authors

Giorgio Gallinella¹, Antonio Marchini²

Affiliations

¹ Department of Pharmacy and Biotechnology, University of Bologna, 40138 Bologna, Italy.
² Laboratory of Oncolytic Virus Immuno-Therapeutics, German Cancer Research Centre, 69120 Heidelberg, Germany.

Abstract

The XVIII International Parvovirus Workshop took place in Rimini, Italy, from 14 to 17 June 2022 as an on-site event, continuing the series of meetings started in 1985 and continuously held every two years. The communications dealt with all aspects of research in the field, from evolution and structure to receptors, from replication to trafficking, from virus-host interactions to clinical and veterinarian virology, including translational issues related to viral vectors, gene therapy and oncolytic parvoviruses. The oral communications were complemented by a poster exhibition available for view and discussion during the whole meeting. The XVIII International Parvovirus Workshop was dedicated to the memory of our dearest colleague Mavis Agbandje-McKenna (1963-2021).

Keywords: Parvoviridae; conference report; international workshop.

Publication types

Congress
Research Support, Non-U.S. Gov't

MeSH terms

Genetic Vectors
Humans
Italy
Parvoviridae Infections*
Parvovirus* / genetics

Grants and funding

The meeting organization was primarily financed by attendants through a registration fee. The venue was located in an academic building of the University of Bologna, Campus of Rimini. The Journal Viruses provided two travel grant awards. Additionally, sponsoring was provided by the following companies: Axion Biosystems (Atlanta, GA, USA); RegenxBio (Rockville, MD, USA); VectorBuilder (Neu-Isenburg, Germany); Vir/Humabs (Bellinzona, Switzerland); Agilent (Santa Clara, CA, USA); Homology Medicine (Bedford, MA, USA); and Lacerta Therapeutics (Alachua, FL, USA).